# Reduced MGE burden, virulence optimization, and acid stress tolerance shape the clonal succession of MRSA ST59

**Authors:** Ye Jin, Wangxiao Zhou, Xu Dong, Qi Ge, Pan Chen, Yongchang Xu, Ping Shen, Beiwen Zheng, Yonghong Xiao

PMC · DOI: 10.1126/sciadv.aeb3121 · 2026-03-11

## TL;DR

MRSA ST59 outcompetes ST239 in China due to reduced resistance, optimized virulence, and better acid tolerance.

## Contribution

Identifies evolutionary and functional traits enabling ST59's epidemiological dominance over ST239.

## Key findings

- ST59 has reduced MGE burden and retains key virulence genes, unlike ST239.
- Deletions in chp and sraP impair ST59's survival and adhesion, but it shows enhanced acid tolerance.
- ST239's decline is linked to multidrug resistance costs and genome degradation.

## Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) ST59 clone has replaced the historically dominant ST239 in China. However, the mechanisms behind this shift remain elusive. Phylogenetic analysis revealed divergent evolutionary trajectories: ST239 emerged via interlineage recombination and accumulated extensive resistance and genome degradation, whereas ST59 followed a more conserved, recombination-sparse path marked by reduced mobile genetic element (MGE) burden and retention of key virulence–associated MGEs. ST239’s decline was attributed to the fitness costs of multidrug resistance, widespread pseudogenization, and a closed pan-genome. Furthermore, ST59 exhibited enhanced virulence. Two key virulence determinants were identified: deletion of chp impaired survival in whole blood and neutrophil cocultures by disrupting C5a-mediated chemotaxis; sraP deletion reduced epithelial adhesion, nasal colonization, and systemic virulence. ST59 also demonstrated superior acid tolerance, linked to transcriptomic activation of transport and metabolic pathways. Our findings highlight that the epidemiological success of clones requires a balance of reduced resistance, targeted virulence, and environmental adaptability.

Epidemiological success of MRSA ST59 reflects reduced resistance burden, targeted virulence, and enhanced environmental tolerance.

## Linked entities

- **Genes:** CHP1 (calcineurin like EF-hand protein 1) [NCBI Gene 11261], SRA1 (steroid receptor RNA activator 1) [NCBI Gene 10011]
- **Diseases:** MRSA (MONDO:0100073)
- **Species:** Staphylococcus aureus (taxon 1280)

## Full-text entities

- **Genes:** DNASE1 (deoxyribonuclease 1) [NCBI Gene 1773] {aka DNL1, DRNI}, Ctnna2 (catenin alpha 2) [NCBI Gene 12386] {aka Catna, Catna2, cdf, chp}, Selenok (selenoprotein K) [NCBI Gene 80795] {aka 1110001C03Rik, HSPC030, Hsp30, Selk}, C5AR1 (complement C5a receptor 1) [NCBI Gene 728] {aka C5A, C5AR, C5R1, CD88}, Sra1 (steroid receptor RNA activator 1) [NCBI Gene 24068] {aka Sra, Srap, Straa1, Strra1}, Pax6 (paired box 6) [NCBI Gene 18508] {aka 1500038E17Rik, AEY11, Dey, Gsfaey11, Pax-6, Sey}, scb (scabby) [NCBI Gene 20242], SRA1 (steroid receptor RNA activator 1) [NCBI Gene 10011] {aka SRA, SRAP, STRAA1, pp7684}, Fpr1 (formyl peptide receptor 1) [NCBI Gene 14293] {aka FPR, LXA4R, fMLF-R}, Enpep (glutamyl aminopeptidase) [NCBI Gene 13809] {aka 6030431M22Rik, APA, Bp-1/6C3, Ly-51, Ly51}, ARC (activity regulated cytoskeleton associated protein) [NCBI Gene 23237] {aka Arg3.1, hArc}, seb (seborrheic dermatitis) [NCBI Gene 20331], CHP1 (calcineurin like EF-hand protein 1) [NCBI Gene 11261] {aka CHP, SLC9A1BP, SPAX9, Sid470p, p22, p24}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, C5ar1 (complement component 5a receptor 1) [NCBI Gene 12273] {aka C5aR, C5r1, Cd88, D7Msu1}
- **Diseases:** Bacterial (MESH:D001424), CHIPS (MESH:D013203), BSI (MESH:D018805), necrosis (MESH:D009336), MGE (MESH:D014086), cytotoxic (MESH:D064420), infected (MESH:D007239), spa type t437 (MESH:D006969), necrotic lesions (MESH:D009059), Skin lesion (MESH:D012871), Skin abscess (MESH:D000038), inflammation (MESH:D007249), HA (MESH:C537629), AMR (MESH:D060467)
- **Chemicals:** glycopeptide (MESH:D006020), trimethoprim-sulfamethoxazole (MESH:D015662), HSA (MESH:D006585), daptomycin (MESH:D017576), ATP (MESH:D000255), CO2 (MESH:D002245), oxacillin (MESH:D010068), reactive oxygen species (MESH:D017382), saponin (MESH:D012503), beta-lactams (MESH:D047090), fosfomycin (MESH:D005578), tetracycline (MESH:D013752), penicillin (MESH:D010406), CP003166.2 (-), H2O2 (MESH:D006861), amikacin (MESH:D000583), fluoroquinolones (MESH:D024841), linezolid (MESH:D000069349), rifampicin (MESH:D012293), urea (MESH:D014508), heme (MESH:D006418), vancomycin (MESH:D014640), nucleotide (MESH:D009711), iron (MESH:D007501), levofloxacin (MESH:D064704), tetracyclines (MESH:D013754), imidazole (MESH:C029899), clindamycin (MESH:D002981), ethanol (MESH:D000431), erythromycin (MESH:D004917), gentamicin (MESH:D005839), moxifloxacin (MESH:D000077266), SDS (MESH:D012967), hydrochloric acid (MESH:D006851), aminoglycosides (MESH:D000617), ammonia (MESH:D000641), NaCl (MESH:D012965), sodium deoxycholate (MESH:D003840), ciprofloxacin (MESH:D002939), tigecycline (MESH:D000078304), lincosamides (MESH:D055231), His (MESH:D006639), fMLP (MESH:D009240), phorbol 12-myristate 13-acetate (MESH:D013755)
- **Species:** Listeria monocytogenes (species) [taxon 1639], Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280], Staphylococcus aureus CN79 (strain) [taxon 1242970], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** 003923.1 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TB02), BL21 (DE3) — Mus musculus (Mouse), Hybridoma (CVCL_B7HM), TIB-202 — Sarcophilus harrisii (Tasmanian devil), Devil facial tumor disease 2, Cancer cell line (CVCL_LB80), ST59 — Aedes aegypti (Yellowfever mosquito), Spontaneously immortalized cell line (CVCL_Z617), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), ST239 — Mus musculus (Mouse), Hybridoma (CVCL_L687), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978222/full.md

---
Source: https://tomesphere.com/paper/PMC12978222